Our best interest is to have the highest efficacy %s It's all in our interest that TLT presents the highest possible efficacy %s to the FDA. We will have to live with this in a FDA news release (as the FDA always releases a news justifying a decision).
We only have one chance to make good impression.
TLT management know what's coming in terms of patients and what all this implies.
A date, just for a date, could prove to be less valuable for the stock price over the mid-to-long term.